Literature DB >> 33658642

Neuroinflammatory changes of the normal brain tissue in cured mice following combined radiation and anti-PD-1 blockade therapy for glioma.

Mariano Guardia Clausi1,2, Alexander M Stessin3,4, Zirun Zhao1,2, Stella E Tsirka2, Samuel Ryu5.   

Abstract

The efficacy of combining radiation therapy with immune checkpoint inhibitor blockade to treat brain tumors is currently the subject of multiple investigations and holds significant therapeutic promise. However, the long-term effects of this combination therapy on the normal brain tissue are unknown. Here, we examined mice that were intracranially implanted with murine glioma cell line and became long-term survivors after treatment with a combination of 10 Gy cranial irradiation (RT) and anti-PD-1 checkpoint blockade (aPD-1). Post-mortem analysis of the cerebral hemisphere contralateral to tumor implantation showed complete abolishment of hippocampal neurogenesis, but neural stem cells were well preserved in subventricular zone. In addition, we observed a drastic reduction in the number of mature oligodendrocytes in the subcortical white matter. Importantly, this observation was evident specifically in the combined (RT + aPD-1) treatment group but not in the single treatment arm of either RT alone or aPD-1 alone. Elimination of microglia with a small molecule inhibitor of colony stimulated factor-1 receptor (PLX5622) prevented the loss of mature oligodendrocytes. These results identify for the first time a unique pattern of normal tissue changes in the brain secondary to combination treatment with radiotherapy and immunotherapy. The results also suggest a role for microglia as key mediators of the adverse treatment effect.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33658642      PMCID: PMC7930115          DOI: 10.1038/s41598-021-84600-3

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  31 in total

1.  The immune modulator FTY720 targets sphingosine 1-phosphate receptors.

Authors:  Volker Brinkmann; Michael D Davis; Christopher E Heise; Rainer Albert; Sylvain Cottens; Robert Hof; Christian Bruns; Eva Prieschl; Thomas Baumruker; Peter Hiestand; Carolyn A Foster; Markus Zollinger; Kevin R Lynch
Journal:  J Biol Chem       Date:  2002-04-19       Impact factor: 5.157

Review 2.  PD-1 Inhibitors: Do they have a Future in the Treatment of Glioblastoma?

Authors:  Mustafa Khasraw; David A Reardon; Michael Weller; John H Sampson
Journal:  Clin Cancer Res       Date:  2020-06-11       Impact factor: 12.531

3.  The combination of ionizing radiation and peripheral vaccination produces long-term survival of mice bearing established invasive GL261 gliomas.

Authors:  Elizabeth W Newcomb; Sandra Demaria; Yevgeniy Lukyanov; Yongzhao Shao; Tona Schnee; Noriko Kawashima; Li Lan; J Keith Dewyngaert; David Zagzag; William H McBride; Silvia C Formenti
Journal:  Clin Cancer Res       Date:  2006-08-01       Impact factor: 12.531

Review 4.  Microglia in neurodegenerative disease.

Authors:  V Hugh Perry; James A R Nicoll; Clive Holmes
Journal:  Nat Rev Neurol       Date:  2010-03-16       Impact factor: 42.937

5.  IFN-gamma receptor signaling mediates spinal microglia activation driving neuropathic pain.

Authors:  Makoto Tsuda; Takahiro Masuda; Junko Kitano; Hiroshi Shimoyama; Hidetoshi Tozaki-Saitoh; Kazuhide Inoue
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-20       Impact factor: 11.205

6.  Acute demyelination following radiotherapy for glioma: a cautionary tale.

Authors:  Marina Milic; Jeremy H Rees
Journal:  Pract Neurol       Date:  2016-09-09

7.  Extreme sensitivity of adult neurogenesis to low doses of X-irradiation.

Authors:  Shinichiro Mizumatsu; Michelle L Monje; Duncan R Morhardt; Radoslaw Rola; Theo D Palmer; John R Fike
Journal:  Cancer Res       Date:  2003-07-15       Impact factor: 12.701

8.  Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial.

Authors:  Christina A Meyers; Jennifer A Smith; Andrea Bezjak; Minesh P Mehta; James Liebmann; Tim Illidge; Ian Kunkler; Jean-Michel Caudrelier; Peter D Eisenberg; Jacobus Meerwaldt; Ross Siemers; Christian Carrie; Laurie E Gaspar; Walter Curran; See-Chun Phan; Richard A Miller; Markus F Renschler
Journal:  J Clin Oncol       Date:  2004-01-01       Impact factor: 44.544

9.  Repolarized macrophages, induced by intermediate stereotactic dose radiotherapy and immune checkpoint blockade, contribute to long-term survival in glioma-bearing mice.

Authors:  Alexander M Stessin; Mariano Guardia Clausi; Zirun Zhao; Hong Lin; Wei Hou; Zhao Jiang; Timothy Q Duong; Stella E Tsirka; Samuel Ryu
Journal:  J Neurooncol       Date:  2020-03-25       Impact factor: 4.130

10.  Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma.

Authors:  Mira A Patel; Jennifer E Kim; Debebe Theodros; Ada Tam; Esteban Velarde; Christina M Kochel; Brian Francica; Thomas R Nirschl; Ali Ghasemzadeh; Dimitrios Mathios; Sarah Harris-Bookman; Christopher C Jackson; Christina Jackson; Xiaobu Ye; Phuoc T Tran; Betty Tyler; Vladimir Coric; Mark Selby; Henry Brem; Charles G Drake; Drew M Pardoll; Michael Lim
Journal:  J Immunother Cancer       Date:  2016-05-17       Impact factor: 13.751

View more
  2 in total

Review 1.  DNA Damage Repair in Brain Tumor Immunotherapy.

Authors:  Shihong Zhao; Boya Xu; Wenbin Ma; Hao Chen; Chuanlu Jiang; Jinquan Cai; Xiangqi Meng
Journal:  Front Immunol       Date:  2022-01-13       Impact factor: 7.561

2.  Irradiation-Modulated Murine Brain Microenvironment Enhances GL261-Tumor Growth and Inhibits Anti-PD-L1 Immunotherapy.

Authors:  Joel R Garbow; Tanner M Johanns; Xia Ge; John A Engelbach; Liya Yuan; Sonika Dahiya; Christina I Tsien; Feng Gao; Keith M Rich; Joseph J H Ackerman
Journal:  Front Oncol       Date:  2021-06-24       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.